Tek doz venlafaksin kullanımına bağlı gelişen Nöroleptik malign sendrom

Nöroleptik malign sendrom (NMS) antipsikotik tedavinin nadir görülen fakat potansiyel olarak hayatı tehdit eden bir komplikasyonudur. NMS ço ğ unlukla kendisini ekstra- piramidal bulgular, hiperrefleksi, bilinç ve kan bası nc ı de ğ iş iklikleri ş eklinde gösteren bir tablodur. Ate ş , kas rijiditesi, tremor, otonomik disregülasyon bulgular ı , mental durum de ğ iş ikliğ i ve laboratuar anomalileriyle (yükselmiş kreatin fosfokinaz, polimorfonükleer lökositozis, yükselmiş karaciğ er enzimleri ve myoglobinüri) karakterize bir tablodur. Genellikle antipsikotik kullan ı m ı na ba ğ l ı olarak ortaya çı kar. Biz bu yaz ı da tek doz venlafaksin al ı m ı na ba ğ l ı geliş en nöroleptik malign sendrom vakas ı n ı sunmayı amaçlad ı k.

Neuroleptic malignant syndrome that develops with using of a single dose venlafaxine

Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening complication of antipsychotic medication. NMS shows itself with extrapyramidal symptoms, hyperreflexia, changes in consciousness and blood pressure. It is a condition that’s characterized by fever, muscular rigidity, tremor, the autonomical dysregulation symptoms, mental status changes and laboratory abnormalities (elevated creatine phosphoki- nase, polymorphonuclear leucocytosis, elevated liver enymes and myoglobinuria). NMS is commonly triggered by antipsychotic drug use. Herein we aimed to present a case report about neuroleptic malignant syndrom that develops with using of a single dose venlafaksin.

Kaynakça

1. Védie C, Poinso F, Hemmi F, Rivet B. Major symptoms and differential diagnosis of neuroleptic malignant syndrome: three case reports. Eur Psychiatry 2000;15:334-7.

2. Fekadu A, Bisson JI. Neuroleptic malignant syndrome: Diagnostic and therapeutic dilemmas. Behav Neurol 2005;16:9-13.

3. İşeri P, Selekler M. Noroleptik malign sendrom. Turkiye Klinikleri J Int Med Sci 2005;1:39-42.

4. Delay J, Deniker P. Drug-induced extra-pyramidal syndromes. In Handbook of Clinical Neurology. Vol. 6: Diseases of the Basal Ganglia (Eds PS Vinken, GW Bruyn): 248–266. North-Holland, New York, Elsevier, 1968.

5. Sarkar P, Natarajan C, Gode N. Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients. Indian J Psychiatry 2009;51:202-5.

6. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23:477-92. 1. 7.Caroff SN, Rosenberg H, Mann SC, Campbell EC, Sullivan KA. Neuroleptic malignant syndrome in the critical care unit. Crit Care Med 2002;30:2609–10.

7. Langlow JR, Alarcon RD. Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. J Clin Psychiatry 1989;50:144-5.

8. Gupta S, Racaniello AA. Neuroleptic malignant syndrome associated with amoxapine and lithium in an older adult. Ann Clin Psychiatry 2000;12:107-9.

9. Tsai HC, Kuo PH, Yang PC. Fever, consciousness disturbance, and muscle rigidity in a 68-year-old man with depressive disorder. Chest 2003;124:1598-601.

10. Nimmagadda SR, Ryan DH, Atkin SL. Neuroleptic malignant syndrome after venlafaxine. Lancet 2000;354:289-90.

11. Lu TC, Chu PL, Wu CS, Tsai KC, Chen WJ. Neuroleptic malignant syndrome after the use of venlafaksin in a patient with generalized anxiety disorder. J Formos Med Assoc 2006;105:90-3.

12. Redrobe, JP, Bourin M, Colombel MC, Baker GB. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 1998;138:1–8.

13. Goldberg RJ. Selective serotonin reuptake inhibitors: infrequent medical adverse effects. Arch Family Med 1998; 7:78–84.

14. Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ 2003;169:43

15. Doğan N, Kürşad H, Erdem AF, Kızılkaya M. Noroleptik malign sendromda nadir etyolojik faktorler ve klinik seyir. AUTD 2003;35:23-6.

16. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome. Psychiatr Serv 1998; 49:1163-72.

17. Mathews T, Aderibigbe YA. Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 1999;2:129- 144.

18. Taniguchi N, Tanii H, Nishikawa T. Classification system of complications in neuroleptic malignant syndrome. Methods Find Exp Clin Pharmacol 1997;19:193-9.

19. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989;50:18-25.

20. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65:464-70.

21. Simon HB. Hyperthermia. N Engl J Med 1993;329:483-7.

22. Stahl MS. Essential Psychopharmacology. Cambridge: Cambridge University 2000; p:245-97.

23. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. Eleventh ed. Hudson, OH: Lexi-Comp, 2003.

24. Woods G, Taggart C, Boggs R, Cadden I. Neuroleptic malignant syndrome associated with quetiapine and venlafaxine use: a case report and discussion. Ther Adv Psychopharmacol 2013;3:53-5.

25. Mannaioni G, Baronti R, Moroni F. Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome. Ther Clin Risk Manag 2005;1:225-9.

Kaynak Göster

Yeni Tıp Dergisi
  • ISSN: 1300-2317
  • Yayın Aralığı: Yılda 0 Sayı
  • Başlangıç: 2018

700119

Sayıdaki Diğer Makaleler

Application of modern biotechnological methods in complex treatment of deep burns

Kamoliddin SALAHIDDINOV, Andrey ALEXEEV, Boris GAVRILYUK

Crohn hastalığında aktivite tayininde dinamik kontrastlı ve difüzyon ağırlıklı incelemelerin konvansiyonel manyetik rezonans enterografiye katkısı

Seçil Telli ERDOĞAN, Esin YENCİLEK, Gamze KILIÇOĞLU, Direnç Özlem AKSOY, Koray KOÇHAN, Mehmet Masum ŞİMŞEK

Antikoagülasyonda yeni ajanlar

Fatma KEREN, Özlem BALÇIK ŞAHİN

Epiploic appendagitis after laparoscopic total hysterectomy suggested an ureter injury

İkbal KAYGUSUZ, HİLAL USLU YUVACI, İlknur İnegöl GÜMÜŞ, Önder SÜRGİT, Aslı KÖKTENER

The effect of semi-quantitative analysis of dynamic contrast enhanced MRI on differential diagnosis of breast masses

Direnç Özlem AKSOY, Zeynep Gamze KILIÇOĞLU, Seçil Telli ERDOĞAN, Tuğba ATASOY, Esin YENCİLEK, Mehmet Masum ŞİMŞEK, BARIŞ ERDOĞAN

Erişkinde büyüme hormonu eksikliğinin değerlendirilmesi ve tedavisi

Hüseyin DEMİRCİ, Bilge CEYDİLEK

Do we really need to perform the original sistrunk operation when treating thyroglossal duct cysts?

Engin YILMAZ, ÇAĞATAY EVRİM AFŞARLAR, AYŞE KARAMAN, İBRAHİM KARAMAN, Ismet Faruk OZGUNER, Derya ERDOĞAN, Yusuf Hakan ÇAVUŞOĞLU

Tek doz venlafaksin kullanımına bağlı gelişen Nöroleptik malign sendrom

Bahadır KÖSEM

Tibianın konjenital psödoartrozu

ERDOĞAN BÜLBÜL, Bahar YANIK, GÖKHAN MERİÇ, Gülen DEMİRPOLAT

Sitagliptin tedavisinin total antioksidan kapasite ve kan şekeri üzerine etkileri

Mehmet Yavuz GÜRLER, Umut HAKLIGİL, Fatih BORLU, Ekmel Burak ÖZŞENEL, Güzin KARATEMİZ, Emrah Erkan MAZI, Seyit UYAR, Fergial MOUEMINOGLU